IGBA And WHO Ally On Access Ambitions

Global Generics And Biosimilars Organization Meets With WHO Director General

IGBA representatives have met with the WHO director general to build on efforts to expand global access to generics and biosimilars.

WHO
The IGBA and WHO are collaborating on expanding access to generics and biosimilars

Representatives of the International Generics and Biosimilars Medicines Association, including members of the group’s CEO advisory committee, have met with World Health Organization director general Tedros Adhanom Ghebreyesus in Geneva to build on collaborative efforts to expand global access to generics and biosimilars.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Iconovo Slims Down As It Focuses On Commercialization

 
• By 

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By 

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

How To Make The Most Of Your GGB Awards Entries

 
• By 

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By 

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

More from Products

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By 

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

How To Make The Most Of Your GGB Awards Entries

 
• By 

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Denosumab Race Heats Up In Europe With Eight More Nods

 
• By 

Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.